搜索
Vyne Therapeutics Inc
VYNE添加自选
0.670USD
-0.000-0.06%
交易中 （美东）报价延迟15分钟
22.33M总市值
亏损市盈率 TTM
查看详细走势图
盘中分时
1分
30分
1小时
日k
周k
月k
日k
今天
-0.06%
5天
-0.52%
1月
+7.56%
6月
+78.95%
今年开始到现在
+15.50%
1年
-46.83%
TradingKey Vyne Therapeutics Inc股票评分
单位: USD 更新时间: 2026-05-14操作建议
Vyne Therapeutics Inc当前公司基本面数据相对非常健康，最新ESG披露属于行业领先水平。增长潜力很大。当前估值合理，在生物技术与医疗研究行业排名175/382位。机构持股占比非常高，近一月多位分析师给出公司评级为买入。最高目标价2.00。中期看，股价处于上升通道。近一个月，市场表现较强，基本面评分较高，但较强的走势得没有得到技术面的印证。目前股价在压力位和支撑位之间，可以做区间波段操作。
Vyne Therapeutics Inc评分
压力支撑
由于公司未披露，未能获取相关数据
多维评测
本期评分
上期评分
公司舆情
过去24小时
热度
过冷
过热
中性
Vyne Therapeutics Inc亮点
亮点风险
VYNE Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on developing differentiated therapies to treat chronic inflammatory and immune-mediated conditions with high unmet need. Its lead program is repibresib gel (also known as VYN201), a topically administered, small-molecule pan-BD bromodomain and extra-terminal (BET) inhibitor designed as a soft drug to address diseases involving multiple, diverse inflammatory cell signaling pathways while providing low systemic exposure. Its second program is VYN202, an oral, small-molecule BD2-selective BET inhibitor. The Company has rights to research, develop and commercialize products containing BET inhibitor compounds for the treatment of any disease, disorder or condition in humans. Utilizing its InhiBET platform and through its preclinical and clinical activities, the Company is evaluating the impact that BET inhibitor compounds have on regulating pro-inflammatory cytokines.
业绩高增长
公司营业收入稳步增长，连续3年增长34.43%
业绩增长期
公司处于发展阶段，最新年度总收入570.00K美元
估值低估
公司最新PE估值-1.08，处于3年历史低位
机构减仓
最新机构持股11.08M股，环比减少13.12%
先锋集团持仓
明星投资者先锋集团持仓，最新持仓市值0.00
分析师目标
根据
2
位分析师
买入
评级
2.000
目标均价
+198.51%
涨幅空间
数据免责声明：分析师评级与目标价由LSEG提供，仅供参考，不应当作投资建议
Vyne Therapeutics Inc新闻
即将为您带来更多新闻，敬请期待。。。
财务指标
每股收益
由于公司未披露，未能获取相关数据
营业总收入
由于公司未披露，未能获取相关数据
Vyne Therapeutics Inc简介
VYNE Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on developing differentiated therapies to treat chronic inflammatory and immune-mediated conditions with high unmet need. Its lead program is repibresib gel (also known as VYN201), a topically administered, small-molecule pan-BD bromodomain and extra-terminal (BET) inhibitor designed as a soft drug to address diseases involving multiple, diverse inflammatory cell signaling pathways while providing low systemic exposure. Its second program is VYN202, an oral, small-molecule BD2-selective BET inhibitor. The Company has rights to research, develop and commercialize products containing BET inhibitor compounds for the treatment of any disease, disorder or condition in humans. Utilizing its InhiBET platform and through its preclinical and clinical activities, the Company is evaluating the impact that BET inhibitor compounds have on regulating pro-inflammatory cytokines.
公司代码VYNE
公司Vyne Therapeutics Inc
CEODomzalski (David)
网址https://vynetherapeutics.com/
相关品种
